Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

For many patients on tirzepatide, a transformative medication used for ... and she can't afford the list price of around ...

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in ...

Eli Lilly is leading a push with other pharmaceutical companies to request a pause in the Biden administration's drug pricing negotiations, even as officials prepare to release a new list of ...